Business
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s diseaseHOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of a substantive Q-Submission (“Q-Sub”) meeting with the U.S. Food and Drug Administration (“FDA”)
About this update from Nexalin Technology, Inc.
[{"type":"image","alt":"Nexalin Technology, Inc.","displaySize":"","headline":null,"caption":"Nexalin Technology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kPm7LNc3A4iAJ.KL_fneQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76","width":200,"height":200}},"lazy":false},{"type":"text","content":"FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s disease","length":167,"tagName":"p"},{"type":"text","content":"HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of a substantive Q-Submission (“Q-Sub”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding its Gen-2 SYNC™ neurostimulation console for the treatment of Alzheimer’s disease.","length":425,"tagName":"p"},{"type":"text","content":"The meeting focused on Nexalin’s proposed clinical development plan and overall regulatory strategy for the Gen-2 SYNC console in Alzheimer’s disease. As part of the interaction, the Company and the FDA discussed the potential use of the De Novo classification pathway for this indication, reflecting the novel mechanism of action of Nexalin’s deep, frequency-specific neurostimulation technology.","length":397,"tagName":"p"},{"type":"text","content":"The discussion provided a clear understanding of Nexalin’s existing clinical data for the treatment of Alzheimer’s disease. Additional discussions included Nexalin’s plans for new U.S.-based Pilot Studies, followed by a large pivotal study designed to demonstrate the safety and efficacy of the Gen-2 SYNC console in patients with mild to moderate Alzheimer’s disease. Key topics included the design of both the pilot and pivotal trials, with alignment reached on foundational components such as patient population, dosing paradigm, and elements of the statistical analysis plan.","length":579,"tagName":"p"},{"type":"text","content":"Importantly, Nexalin and the FDA also ...